/ /

Clinical Pharmacology

Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.
Four things executives need to know to combat rising drug spendExecutives need to ask themselves four key questions to mitigate the negative impact of rising drug costs.
Biosimilar drugs appear comparable to brand-name counterpartsSystematic review provides comprehensive first look at TNF-alpha biosimilar treatments.

Increased utilization driving pharmacy spend in exchange plansExpress Scripts Exchange Pulse report found that utilization, particularly for traditional meds, was one of the biggest factors driving spending in 2015, accounting for more than half of the exchange plans $99 PMPY increase in spending between 2014 and 2015.
Antibiotic stewardship programs: 4 case studiesAll antibiotic use has the potential to contribute to the development of antibiotic resistance. That’s why it is key to reduce inappropriate antibiotic use in order to slow the growth of resistance.
Survey finds stakeholders lack understanding of biosimilarsIt is important to look at how the introduction of biosimilars in the United States may affect your business and your stakeholders and plan for those changes accordingly, according to a new report.

Experts debate best treatment for metastatic colorectal cancer patientsDe-escalated maintenance or “drug holidays”: What’s best for patients with metastatic colorectal cancer?
How biomarkers can personalize cancer immunotherapyASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies
FORM Test Advertising Article Page
Four critical components for successful, value-based pharma contractsDespite their proliferation, at-risk pharma contracts are still little more than value-based window dressing. Here are four critical components of contracts that can actually move the value meter in the right direction.